TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03724396

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss - BWL
Description: All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss - BWL
Description: All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Novel Executive Function Training - NEXT
Description: Modifies programs like CogSMART and cognitive remediation training to help participants improve executive functioning to adhere to recommendations from BWL.
Study: NCT01359267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-EC-DG
Description: 99mTc-EC-DG will be used before the SPECT/CT scans throughout the study to determine the its effectiveness. 20 mCi of 99mtc-EC-DG will be administered through a vein through a catheter. This will be done before the SPECT/CT scan at 4 weeks and 10 weeks.
Study: NCT02741674

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy (SG) - historical
Description: Participant has had SG, as identified using existing data
Study: NCT02759055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: an EHR-linked, Web-based clinical decision support (CDS) system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke
Study: NCT03840759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inpatient geriatric consultation team
Description: For the intervention group, a geriatric physician was consulted and recommendations were made by the geriatric consultant after a complete CGA.
Study: NCT02081222

Intervention type: PROCEDURE
Intervention: surgery for congenital heart disease with cardiopulmonary bypass
Description: surgery for congenital heart disease with cardiopulmonary bypass
Study: NCT02780830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be provided in hard gelatin capsules in opaque high-density polyethylene bottles. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
Study: NCT03299790

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity interval exercise training (HIIT)
Description: This program includes 24 weeks of exercise training and is divided in different phases (phase 1: week 1-2, equal to the MIT group, phase 2: week 3-6, 6 bouts of high-intensity exercise, phase 3: week 7-12, 7 bouts of high-intensity exercise, phase 4: week 13-24, 8 bouts of high-intensity exercise). The exercise training program consists of 3 exercise sessions per week (for 6 months).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moderate-intensity exercise training (MIT)
Description: This program includes 24 weeks of exercise training and is not devided in phases. The exercise training program consists of 3 endurance exercise sessions per week (for 6 months). The total exercise volume equals the exercise volume of the HIIT group.
Study: NCT00161395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instruction in the Creighton Model Fertility Care System
Description: Instruction in the Creighton Model Fertility Care System.
Study: NCT02587585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback against tailored target
Description: Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. In the active group, the watch will summate activity movement in two hour epochs and the target for the day for that epoch is the activity in the same epoch 24 hours earlier, plus 5%. During an epoch the patient is shown progress towards the target at at the end of an epoch, they will see their final process towards target for that epoch.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No feedback
Description: Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. However the watch face will simply show which epoch a person is in. The watch will collect the activity in exactly the same way over the day.
Study: NCT00694252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.
Study: NCT01522287

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Assisted Cognitive Behavior Therapy (BT STEPS)
Description: BT STEPS is a computer-assisted self help treatment for OCD. Clients work through the program at their own pace.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Assisted Cognitive Behavior Therapy (BT STEPS)
Description: BT STEPS is a computer-assisted self help treatment for OCD. Clients work through the program at their own pace.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Assisted Cognitive Behavior Therapy (BT STEPS)
Description: BT STEPS is a computer-assisted self help treatment for OCD. Clients work through the program at their own pace.
Study: NCT04540341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization
Description: Mulligan mobilization technique will be apply.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization
Description: Core stabilization technique will be apply.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional therapy exercise will be apply.
Study: NCT01826136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella device
Study: NCT03572725

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gas tamponade
Description: Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air tamponade
Description: Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.
Study: NCT01753661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linguistic Feedback Report
Description: Throughout the study, parents will complete 16 total LENA recordings. The feedback report will include information on the parent's previous LENA recording(s), including the Adult Word Count (AWC), Conversational Turns (CTC), and TV Time (TVT). Parents in the treatment group will receive feedback reports for the baseline and 10 weekly recordings. Feedback reports will not be offered for the follow-up recordings

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia Education Sessions
Description: Treatment group parents will receive 10 weekly home visit sessions (e.g. the ASPIRE Program) with an interventionist during which time they will review multimedia education modules. The sessions include feedback report review, module discussion, video modeling, and goal setting activities. The education modules provide parents with information on supporting the development of listening and spoken language for children with hearing loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EI-As-Usual
Description: The EI-as-usual condition will parallel the treatment condition. Families in the EI-as-usual condition will continue to receive their usual therapy. They will not participate in Project ASPIRE home visits or receive feedback on their recordings. Families in this group will complete the same assessments as the families in the treatment group.
Study: NCT04164251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening mammography
Description: The purpose of the study was to evaluate the feasibility of securing inpatient breast cancer screening mammograms for non-adherent hospitalized women prior to hospital discharge.
Study: NCT01630863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA.
Study: NCT00731562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate Controlled Release
Description: A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate Controlled Release
Description: A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fed conditions
Study: NCT03937908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2g Centella asiatica water extract product
Description: 2g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4g Centella asiatica water extract product
Description: 4g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
Study: NCT04441957

Intervention type: DEVICE
Intervention: Endovenous Mechano- Chemical Ablation
Description: The Flebogrif™ catheter (Balton® Sp. z o.o., Warsaw, Poland) represents endoluminal Non Thermal Non Tumescent devices designed to cause occlusion (fibrosis) of the target vein through the combined mechanical and chemical damage to its endothelial lining with retractable cutters and foamed sclerosant.
Study: NCT04182269

Intervention type: OTHER
Intervention: Measurement of functional exercise capacity
Description: The Glittre Activities of Daily Living (ADL) Test was used to evaluate functional exercise capacity.

Intervention type: OTHER
Intervention: Measurement of functional exercise capacity
Description: The Glittre Activities of Daily Living (ADL) Test was used to evaluate functional exercise capacity.
Study: NCT04114331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise
Description: Manual therapy consisting of soft tissue and joint mobilization to gain mobility. Therapeutic exercise was active motion and resisted motion to gain motor control and motor coordination in the new range.
Study: NCT04645901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SYHA1805 tablets
Description: Oral tablets of SYHA1805 with several doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets of placebo with matching several doses
Study: NCT02588716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Terlipressin will be given as an intravenous injection of 2μg/kg/h to be continued throughout the surgery and weaned off over four hours postoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Same volumes of normal saline infusion, throughout the operation then gradually withdrawn over 4 hours.
Study: NCT01123941

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typherix
Description: 1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVGH Vi-CRM197
Description: 1 dose of 0.5 mL containing 25 mcg of Vi-CRM
Study: NCT05336396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMI
Description: Longitudinal data will be collected to determine the effectiveness of BMI compared to traditional OHI to maintain and improve periodontal health.
Study: NCT04210388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 tablet, Formulation A
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 tablet, Formulation B
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 tablet, Formulation C
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Study: NCT00161395

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preconception advice
Description: Preconception advice for diet and frequency of intercourse.
Study: NCT00920023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Superparamagnetic Iron Oxide Magnetic Resonance Imaging
Description: Two MRIs will be performed over a two day period. The second scan will be done 48 hours after intravenous infusion of ferumoxytol
Study: NCT00578721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg taken daily with an arginine-restricted diet
Study: NCT04210388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 tablet, Formulation D
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation D under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD5718 film-coated tablet, Reference treatment
Description: Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Study: NCT04684628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA PET/CT
Description: Administration of 68Ga-PSMA-11 followed by a PET/CT scan at 45 min after injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA PET/CT
Description: Administration of 68Ga-PSMA-11 followed by a PET/CT scan at 45 min after injection.
Study: NCT03444948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-RFA using Habib Tm as a probe
Description: 3 EUS-RFA interventions at 1-month interval

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS
Description: Standard intervention
Study: NCT01891565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Study: NCT03575299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The adoptive treatment of allogeneic γδT cells
Description: Allogeneic γδT cells will be administered to patients with MDR-TB every two weeks, for 12 times in a total of 6 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No allogeneic γδT cells will be administered to patients with MDR-TB.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional treatment
Description: Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.
Study: NCT02992977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AutoSynVax™ vaccine
Description: AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
Study: NCT00614523

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Study: NCT03721692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC
Description: The patients will use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
Study: NCT00616616

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single incision laparoscopic surgery
Description: Surgery will be performed with ine laparoscopic incision
Study: NCT00582504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEE TC-83
Description: Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper outer aspect of arm
Study: NCT00630721

Intervention type: OTHER
Group type: OTHER
Intervention: IFNbeta-1b
Description: no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
Study: NCT01310634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Description: Parents of hospitalized neonates received comprehensive intervention program,including parent educational-behavioral intervention program, effective doctor/nurse parent communication,regularly visit the neonatal ward and care the hospitalized neonates under the guidance of a doctor.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Comprehensive intervention
Description: Parents of hospitalized neonates received comprehensive intervention program,including parent educational-behavioral intervention program, effective doctor/nurse parent communication,regularly visit the neonatal ward and care the hospitalized neonates under the guidance of a doctor.
Study: NCT02041143

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk protein
Description: Study product will provide 25 g of protein to subjects.
Study: NCT04268992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-term exercise
Description: All patients randomised to long-term exercise will perform exercise training at least three times a week for three months. The exercise is supervised and individualised.
Study: NCT01765595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DDI+
Study: NCT02041143

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Product with no protein
Study: NCT02349919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procaterol
Description: Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
Study: NCT02087501

Intervention type: DEVICE
Group type: OTHER
Intervention: Horizon™ Abdominal Aortic Aneurysm Stent Graft System
Description: All patient eligible to undergo stent implantation will receive the Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System.